Epidemiology and Control of Mansonella Perstans Infection in Uganda - Full Text View

Purpose

Mansonella perstans (M. perstans) infection is widespread in Uganda. Knowledge about the epidemiology of this infection, and of the morbidity it induces is poor, and no effective treatment is available. The study aims at providing data on diagnostic, epidemiological, morbidity and treatment aspects of M. perstans infections in Uganda.

Condition	Intervention
Mansonelliasis Pruritus Lymphoedema Abdominal Pains	Drug: ivermectin and albendazole

Genetics Home Reference related topics:

lymphedema-distichiasis syndrome

MedlinePlus related topics:

Abdominal Pain Itching Lymphedema

ChemIDplus related topics:

Albendazole Ivermectin

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study

Official Title:	Studies on the Epidemiology and Control of Mansonella Perstans Infection in Uganda

Further study details as provided by DBL -Institute for Health Research and Development:

Primary Outcome Measures:

microfilariae periodicity patterns
epidemiology of M. perstans at community level
clinical spectre among infected
reduction in microfilaraemia

Secondary Outcome Measures:

treatment effect on clinical manifestations

Estimated Enrollment:	1000
Study Start Date:	November 2005
Estimated Study Completion Date:	February 2006

Detailed Description:

Overall objective: to investigate diagnostic, epidemiological and treatment aspects of M. perstans in Uganda with relevance to control

Specific objectives:

To establish the pattern of diurnal periodicity of M. perstans microfilaraemia in humans
To establish the patterns of M. perstans microfilaraemia and possible clinical manifestations related to this infection in two communities with medium to high endemicity
To determine the efficacy of ivermectin alone and the combination of ivermectin and albendazole on M. perstans microfilaraemia.

Eligibility

Ages Eligible for Study:	5 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Individuals >= 5 years with or without M. perstans infection

Exclusion Criteria:

Individuals < 5 years
Pregnant women

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00215280

Locations


Uganda, Luwero and Mukono Districts
	Luwero
	Luwero and Mukono, Luwero and Mukono Districts, Uganda

Sponsors and Collaborators

DBL -Institute for Health Research and Development

Vector control Division, Kampala, Uganda

Investigators


Principal Investigator:	Asanta M Asio, Msc	Vector control Division, Kampala, Uganda

More Information

Related Info This link exits the ClinicalTrials.gov site

Study ID Numbers:	MV917090205
First Received:	September 21, 2005
Last Updated:	April 19, 2007
ClinicalTrials.gov Identifier:	NCT00215280
Health Authority:	Uganda: National Council for Science and Technology

Keywords provided by DBL -Institute for Health Research and Development:

Mansonella perstans

microfilaraemia

ivermectin

albendazole

Uganda

microfilaraemia

Study placed in the following topic categories:

Pruritus

Skin Diseases

Signs and Symptoms, Digestive

Abdominal Pain

Dipetalonema Infections

Filariasis

Pain

Nematode Infections

Albendazole

Lymphedema

Signs and Symptoms

Lymphatic Diseases

Mansonelliasis

Ivermectin

Parasitic Diseases

Acanthocheilonemiasis

Helminthiasis

Additional relevant MeSH terms:

Skin Manifestations

Anti-Infective Agents

Antiprotozoal Agents

Molecular Mechanisms of Pharmacological Action

Antineoplastic Agents

Antiplatyhelmintic Agents

Mitosis Modulators

Anthelmintics

Antimitotic Agents

Pharmacologic Actions

Anticestodal Agents

Spirurida Infections

Antiparasitic Agents

Therapeutic Uses

Tubulin Modulators

Secernentea Infections

ClinicalTrials.gov processed this record on August 20, 2008

Sponsors and Collaborators:	DBL -Institute for Health Research and Development Vector control Division, Kampala, Uganda
Information provided by:	DBL -Institute for Health Research and Development
ClinicalTrials.gov Identifier:	NCT00215280